• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Savara, Inc. - Common Stock (NQ:SVRA)

    6.020 +0.120 (+2.03%)
    Streaming Delayed Price Updated: 3:58 PM EDT, Jun 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,144,058
    Open 5.900
    Bid (Size) 6.010 (9,500)
    Ask (Size) 6.020 (400)
    Prev. Close 5.900
    Today's Range 5.845 - 6.020
    52wk Range 1.980 - 7.005
    Shares Outstanding 114,066,080
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline ↗
    This clinical-stage biotech focused on rare lung diseases reported significant insider selling amid a year of strong share gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire

    Performance

    YTD
    +6.7%
    +6.7%
    1 Month
    +15.8%
    +15.8%
    3 Month
    +19.2%
    +19.2%
    6 Month
    -4.9%
    -4.9%
    1 Year
    +164.0%
    +164.0%

    More News

    Read More
    News headline image
    Savara Announces Chief Financial and Administrative Officer Transition
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
    From Savara Inc.
    Via Business Wire
    News headline image
    What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
    Via The Motley Fool
    News headline image
    Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Reports First Quarter Financial Results and Provides Business Update
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
    From Savara Inc.
    Via Business Wire
    News headline image
    VR Adviser Adds Over 1 Million Savara Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces Participation in 2026 Citizens Life Sciences Conference
    From Savara Inc.
    Via Business Wire
    News headline image
    SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy ↗
    Via Stocktwits
    Topics Intellectual Property Lawsuit
    Get insights into the top gainers and losers of Friday's after-hours session. ↗
    Via Chartmill
    News headline image
    Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces New Employment Inducement Grant
    From Savara Inc.
    Via Business Wire
    News headline image
    Savara Announces Participation in Upcoming Investor Healthcare Conferences
    From Savara Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Savara, Inc. - Common Stock publicly traded?
    Yes, Savara, Inc. - Common Stock is publicly traded.
    What exchange does Savara, Inc. - Common Stock trade on?
    Savara, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Savara, Inc. - Common Stock?
    The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market
    What is the current price of Savara, Inc. - Common Stock?
    The current price of Savara, Inc. - Common Stock is 6.020
    When was Savara, Inc. - Common Stock last traded?
    The last trade of Savara, Inc. - Common Stock was at 06/29/26 03:58 PM ET
    What is the market capitalization of Savara, Inc. - Common Stock?
    The market capitalization of Savara, Inc. - Common Stock is 686.68M
    How many shares of Savara, Inc. - Common Stock are outstanding?
    Savara, Inc. - Common Stock has 687M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.